上海博迅医疗生物仪器股份有限公司 募集资金存放与使用情况鉴证报告 大华核字[2024]0011004202 号 大华会计师事务所 (特殊普通合伙 ) Da Hua Certified Public Accountants（Special General Partnership） 上海博迅医疗生物仪器股份有限公司 募集资金存放与使用情况鉴证报告 （2023 年度） 目 录 页 次 一、 募集资金存放与使用情况鉴证报告 1-2 二、 上海博迅医疗生物仪器股份有限公司 2023 年 度募集资金存放与使用情况的专项报告 1-7 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 募集资金存放与使用情况鉴证报告 大华核字[2024] 0011004202 号 上海博迅医疗生物仪器股份有限公司全体股东： 我们审核了后附的上海博迅医疗生物仪器股份有限公司（以下简 称博迅生物公司）《2023 年度募集资金存放与使用情况的专项报告》 （以下简称"募集资金 ...

关于上海博迅医疗生物仪器股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为上海 博迅医疗生物仪器股份有限公司（以下简称"博迅生物"或"公司"）向不特定 合格投资者公开发行股票并在北交所上市的保荐机构，根据《证券发行上市保荐 业务管理办法》《北京证券交易所证券发行上市保荐业务管理细则》《北京证券交 易所股票上市规则（试行）》等有关规定，对博迅生物使用部分暂时闲置募集资 金进行现金管理事项进行了核查，有关情况如下： 一、募集资金基本情况 2023 年 7 月 20 日，中国证券监督管理委员会出具《关于同意上海博迅医疗 生物仪器股份有限公司向不特定合格投资者公开发行股票注册的批复》（证监许 可〔2023〕1585 号），同意公司向不特定合格投资者公开发行股票的注册申请。 经北京证券交易所《关于同意上海博迅医疗生物仪器股份有限公司股票在北京证 券交易所上市的函》（北证函〔2023〕344 号）批准，公司股票于 2023 年 8 月 17 日在北京证券交易所上市。 国金证券股份有限公司 公司本次向不特定合格投资者发行普通股 8,333,100 股 ...

证券代码：836504 证券简称：博迅生物 公告编号：2024-017 上海博迅医疗生物仪器股份有限公司 独立董事 2023 年度述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 作为上海博迅医疗生物仪器股份有限公司（以下简称"公司"） 的独立董事，章孝棠先生在任职期间严格按照《公司法》《上海博迅 医疗生物仪器股份有限公司章程》（以下简称"《公司章程》"）《北京 证券交易所上市公司持续监管指引第 1 号——独立董事》的规定，认 真、勤勉、谨慎履行职责，积极出席相关会议，对各项议案进行认真 审议，完成了董事会交办的各项工作任务。现就 2023 年度履行独立 董事职责情况汇报如下： 一、 独立董事的基本情况 章孝棠：男，1963 年 9 月出生，工商管理硕士、经济师、中国 注册会计师、中国注册会计师协会首批资深会员。2022 年 9 月 20 日至今，任上海博迅医疗生物仪器股份有限公司独立董事。 二、 会议出席情况 独立董事章孝棠对公司 2023 年经营活动情况进行了认真的了解 和查验，发表独立意见 ...

证券代码：836504 证券简称：博迅生物 公告编号：2024-007 上海博迅医疗生物仪器股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 3 月 15 日 2.会议召开地点：上海博迅医疗生物仪器股份有限公司会议室 3.会议召开方式：现场表决 4.发出董事会会议通知的时间和方式：2024 年 3 月 4 日以邮件方式通知 5.会议主持人：董事长吕明杰先生 6.会议列席人员：应芸 7.召开情况合法、合规、合章程性说明： 4.提交股东大会表决情况： 会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、规范 性文件和《上海博迅医疗生物仪器股份有限公司章程》（"《公司章程》"）的有 关规定。 （二）会议出席情况 会议应出席董事 5 人，出席和授权出席董事 5 人。 二、议案审议情况 （一）审议通过《关于公司 2023 年董事会工作报告的议案》 1.议案内容： 根据《公司法》和《公司 ...

国金证券股份有限公司 关于上海博迅医疗生物仪器股份有限公司 2023 年度募集资金存放与实际使用情况的专项核查报告 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为上海 博迅医疗生物仪器股份有限公司（以下简称"博迅生物"或"公司"）向不特定 合格投资者公开发行股票并在北交所上市的保荐机构，根据《证券发行上市保荐 业务管理办法》《北京证券交易所上市公司持续监管办法（试行）》《北京证券交 易所证券发行上市保荐业务管理细则》《北京证券交易所股票上市规则（试行）》 等有关规定，对博迅生物 2023 年度募集资金存放与实际使用情况进行了核查， 有关情况如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会证监许可〔2023〕1585 号文核准，并经北京证券 交易所同意，本公司由主承销商国金证券于 2023 年 8 月 8 日向社会公众公开发 行普通股（A 股）股票 750 万股，每股面值 1 元，每股发行价人民币 9.75 元。截 至 2023 年 8 月 11 日，本公司共募集资金 73,125,000.00 元，扣除发行费用 8,949,562.50 元，募集资金净额 6 ...

Company Overview - Shanghai Boxun Medical Biological Instrument Corp. was listed on the Beijing Stock Exchange on August 17, 2023[4]. - The company’s registered capital increased to RMB 43,333,100.00 after issuing 8,333,100 shares in August 2023[22]. - The company’s stock is classified under the manufacturing industry, specifically in the general instruments and experimental analysis instruments manufacturing sector[20]. - The company has undergone multiple certifications, including environmental management and quality management systems, valid until 2026[3]. - The company has been recognized as a "High-tech Enterprise" and a "Specialized, Refined, Characteristic, and Innovative" enterprise at the provincial level[42]. Financial Performance - The company's operating revenue for 2023 was approximately ¥142.27 million, a slight decrease of 0.29% compared to ¥142.68 million in 2022[27]. - The net profit attributable to shareholders for 2023 was approximately ¥26.67 million, reflecting a 0.99% increase from ¥26.41 million in 2022[27]. - The gross profit margin improved to 41.00% in 2023, up from 40.40% in 2022[27]. - Total assets increased by 37.20% year-over-year, reaching approximately ¥267.18 million at the end of 2023, compared to ¥194.74 million at the end of 2022[28]. - The net assets attributable to shareholders rose by 54.55% to approximately ¥193.01 million in 2023, up from ¥124.89 million in 2022[28]. - The net cash flow from operating activities for 2023 was approximately ¥26.24 million, a decrease of 5.84% from ¥27.87 million in 2022[28]. - The company reported a significant increase in non-operating income, which rose by 25,673.20% to 3,500,000.00, primarily due to a subsidy received for listing[58]. - The company’s operating profit for 2023 was 26,278,835.50, representing an 18.47% margin, down from 22.14% in 2022, indicating a decrease of 16.82% year-over-year[53]. - The company reported a net profit of 2,279,023 for the period, indicating strong financial performance[152]. Product Development and R&D - The company’s main products include temperature and humidity control products, high-pressure sterilization products, and purification safety products[20]. - The company launched two new sterilizers in the sterilization product line, filling a gap in the flip-top sterilizer segment[40]. - The company expanded its product offerings in the plant cultivation sector, targeting the high-end market with a specialized product line[40]. - The company is engaged in multiple R&D projects, including a fully automatic high-pressure sterilizer aimed at improving product stability and competitiveness in the high-end market[87]. - The company has established a collaboration with Shanghai University of Technology for upgrading the performance of drug stability testing equipment[89]. - The company’s R&D personnel accounted for 11.38% of total employees, with a total of 27 R&D staff[85]. - R&D expenditure for the current period amounted to 7,829,023.60, representing 5.50% of total revenue, compared to 5.39% in the previous period[83]. Shareholder and Governance - The company’s actual controller is Lv Mingjie, with several associated individuals[21]. - The largest shareholder, Lv Mingjie, holds 26,143,000 shares, representing 60.33% of the total shares[149]. - The company has committed to avoiding any misuse of funds and ensuring no financial transactions outside normal business operations occur with related parties[144]. - The company has implemented strict measures to comply with legal and regulatory requirements regarding related party transactions[143]. - The company has established a framework to ensure that any economic losses due to non-compliance with commitments will be addressed according to relevant laws and regulations[143]. - The company has committed to transparency and accountability in its financial dealings to mitigate potential legal liabilities[143]. Cash Dividend Policy - The company completed a cash dividend distribution of RMB 30,333,170.00, distributing RMB 7.00 per 10 shares based on a total share capital of 43,333,100 shares[5]. - The company prioritizes cash dividends in its profit distribution policy, aiming for a minimum of 30% of the average distributable profit over any three consecutive fiscal years[167]. - The company will conduct cash dividends annually after the shareholders' meeting, with the board able to propose interim cash dividends based on profitability and funding needs[167]. - The company’s cash dividend distribution is contingent upon positive distributable profits and sufficient cash flow to ensure ongoing operations[167]. - The company has established a differentiated cash dividend policy based on its development stage, with a minimum cash dividend ratio of 80% for mature stages without major capital expenditures[169]. Market Trends and Opportunities - The global scientific instrument market is projected to reach $75 billion in 2022, with a CAGR of approximately 5.6% from 2015 to 2022, and China holding over 10% of the market share[194]. - The Chinese life sciences laboratory equipment market grew from $3.8 billion in 2016 to $8.4 billion in 2021, with an expected CAGR of 17.4% until 2026[194]. - The domestic market capacity for the company's key products in 2021 was approximately ¥5.6 billion, indicating significant market potential[197]. - The pharmaceutical industry is a major application area for laboratory equipment, with increasing investments driven by enhanced regulatory standards and quality requirements[199]. - The company is positioned to benefit from the rapid growth of downstream industries such as biopharmaceuticals and CROs, which will drive demand for laboratory equipment[197]. Risk Management - The company faces risks related to the control of its major shareholder, which could impact the interests of minority shareholders if internal controls are ineffective[104]. - The company has implemented measures such as "three meetings" rules and improved internal control systems to mitigate risks from major shareholders[104]. - The company has identified risks associated with new product launches, including potential misalignment with customer needs and competitive performance, which could negatively impact future growth[105]. - The company has identified market demand instability for laboratory equipment and life science instruments as a potential uncertainty factor[103]. - The company emphasizes compliance with industry laws and regulations, enhancing risk management capabilities[100]. Compliance and Legal Matters - The company has not faced any major changes in risk factors during the reporting period, maintaining a consistent risk profile[105]. - The company has not disclosed any major contracts or other significant matters that would impact its operations or financial standing[110]. - The company has confirmed that there are no direct or indirect equity relationships among its major stakeholders and related parties[139]. - The company is currently fulfilling its obligations related to the issuance of shares and compliance with regulatory requirements[138]. - The company is committed to maintaining compliance with all relevant laws and regulations regarding its real estate holdings[138].

上海博迅医疗生物仪器股份有限公司 关于使用部分自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 审议情况 1、审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2023 年 3 月 24 日第三届董事会第九次会议、第三届监事会第六次会议，审议通过《关 于使用部分自有闲置资金购买理财产品的议案》，使用额度不超过 7,000 万元 人民币的闲置资金购买银行中低风险、短期理财产品，在上述额度范围内，资 金可以滚动使用，自股东大会审议通过之日起 12 个月内有效，公司于 2023 年 04 月 18 日召开了 2022 年年度股东大会，审议并通过了该议案。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上 披露的《关于使用部分自有闲置资金购买理财产品的公告》（公告编号：2023- 013） 证券代码：836504 证券简称：博迅生物 公告编号：2024-006 2、披露标准 二、 本次理财情况 （一） 本次理财基本情况 | 受托方 ...

一、 授权现金管理情况 证券代码：836504 证券简称：博迅生物 公告编号：2024-005 上海博迅医疗生物仪器股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 1. 审议情况 公司分别于 2023 年 8 月 24 日、2023 年 9 月 22 日召开了第三届董 事会第十二次会议、第三届董事会第十三次会议，审议通过了《关于使用部分 暂时闲置募集资金进行现金管理的议案》《关于公司调整使用部分暂时闲置募 集资金进行现金管理额度的议案》，同意公司在确保不影响募投项目正常进行、 保证募集资金安全的前提下，公司拟使用最高额度不超过人民币 7,200 万元 闲置募集资金进行现金管理。在前述额度内，资金可以循环滚动使用，有效期 限至公司董事会审议通过之日起 12 个月，公司独立董事已对上述事项发表了 同意的独立意见，公司保荐机构国金证券股份有限公司对上述事项出具了无异 议的核查意见。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse. ...

Financial Performance - The company achieved operating revenue of 142.27 million yuan, a decrease of 0.29% compared to the same period last year[4] - Net profit attributable to shareholders increased by 1.00% to 26.67 million yuan[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 14.14% to 22.25 million yuan[4] - Basic earnings per share decreased by 4.00% to 0.72 yuan[4] Assets and Equity - Total assets at the end of the reporting period were 267.18 million yuan, an increase of 37.20% from the beginning of the period[4] - Shareholders' equity attributable to the company increased by 54.55% to 193.02 million yuan[4] - The total share capital increased by 23.81% to 43.33 million yuan[4] - The net asset value per share attributable to shareholders increased by 24.65% to 4.45 yuan[4] Expenses and Operations - The increase in sales and management expenses was attributed to the expansion of the marketing network and the company's listing on the Beijing Stock Exchange[6] Reporting and Auditing - The financial data presented are preliminary and unaudited, with final figures to be disclosed in the annual report[7]

证券代码：836504 证券简称：博迅生物 公告编号：2024-003 上海博迅医疗生物仪器股份有限公司 关于使用部分自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 审议情况 1、审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2023 年 3 月 24 日第三届董事会第九次会议、第三届监事会第六次会议，审议通过《关 于使用部分自有闲置资金购买理财产品的议案》，使用额度不超过 7,000 万元 人民币的闲置资金购买银行中低风险、短期理财产品，在上述额度范围内，资 金可以滚动使用，自股东大会审议通过之日起 12 个月内有效。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上 披露的《关于使用部分自有闲置资金购买理财产品的公告》（公告编号：2023- 013） | | | | 受托方 | | 产品名 | | 产品金 | 预计年化 | 产品 | | 收益 | | 投资 | 资金 | | | --- | --- | --- | ...